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Abstract 
Background: In Nepal, pre-eclampsia/eclampsia (PE/E) causes an estimated 21% of maternal deaths annually and 
contributes to adverse neonatal birth outcomes. Calcium supplementation has been shown to reduce the risk of PE/E 
for pregnant women and preterm birth. This study presents findings from a cost-effectiveness analysis of a pilot pro-
ject, which provided calcium supplementation through the public sector to pregnant women during antenatal care 
for PE/E prevention as compared to existing PE/E management in Nepal.
Methods: Economic costs were assessed from program and societal perspectives for the May 2012 to August 2013 
analytic time horizon, drawing from implementing partner financial records and the literature. Effects were calculated 
as disability-adjusted life years (DALYs) averted for mothers and newborns. A decision tree was used to model the 
cost-effectiveness of three strategies delivered through the public sector: (i) calcium supplementation in addition to 
the existing standard of care (MgSO4); (ii) standard of care, and (iii) no treatment. Uncertainty was assessed using one-
way and probabilistic sensitivity analyses in TreeAge Pro.
Results: The costs to start-up calcium introduction in addition to MgSO4 were $44,804, while the costs to support 
ongoing program implementation were $72,852. Collectively, these values correspond to a program cost per person 
per year of $0.44. The calcium program corresponded to a societal cost per DALY averted of $25.33 ($25.22–29.50) 
when compared against MgSO4 treatment. Primary cost drivers included rate for facility delivery, costs associated with 
hospitalization, and the probability of developing PE/E. The addition of calcium to the standard of care corresponds to 
slight increases in effect and cost, and has a 84% probability of cost-effectiveness above a WTP threshold of $40 USD 
when compared to the standard of care alone.
Conclusions: Calcium supplementation for pregnant mothers for prevention of PE/E provided with MgSO4 for treat-
ment holds promise for the cost-effective reduction of maternal and neonatal morbidity and mortality associated 
with PE/E. The findings of this study compare favorably with other low-cost, high priority interventions recommended 
for South Asia. Additional research is recommended to improve the rigor of evidence available on the treatment 
strategies and health outcomes.
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Background
Maternal and neonatal morbidity and mortality due to 
preventable causes contribute to a staggering proportion 
of the world’s burden of disease. In 2013, an estimated 
289,000 women died from complications associated 
with pregnancy or childbirth; 27.1% due to hemorrhage, 
14.0% hypertensive disorders, and 10.7% sepsis between 
2003 and 2009 [1, 2]. Among children under five, 45% 
of deaths in 2015 occurred within the first 28  days of 
life with 28% of deaths due to pre-term causes [3–5]. In 
Nepal, an estimated 1500 maternal and 12,000 neona-
tal deaths occurred in 2015 [6, 7]. The country has seen 
reductions in maternal and under-five mortality by 76% 
and 71%, respectively, since 1990 [7, 8]. However, mater-
nal deaths still make up nearly 10% of deaths among 
women of reproductive age and surveys show that the 
reduction in neonatal mortality, at only 34% in Nepal, 
greatly lags behind achievements in under-five and infant 
mortality [5, 8].
Eclampsia is the leading direct cause of maternal mor-
tality in Nepal, occurring in 1 in 25 women and resulting 
in an estimated 21% of maternal deaths annually [9, 10]. 
The condition is also associated with adverse neonatal 
outcomes, including higher rates of neonatal intensive 
care unit admission and length of stay, small for ges-
tational age, stillbirth, and mortality [11–15]. Because 
termination of pregnancy is the definitive management 
of gestational hypertension and eclampsia, such com-
plications remain the leading cause of provider-initiated 
preterm delivery globally [16, 17]. Magnesium sulfate 
(MgSO4) may significantly reduce the risk of recurring 
seizures to as low as 19%, and is used regularly across 
Nepal [10, 18–23]. In some cases, cesarean sections are 
performed to ensure the safety of both mother and child 
[24]. Efforts toward the prevention of pre-eclampsia/
eclampsia (PE/E) may contribute to reductions in mater-
nal and perinatal mortality. In multiple clinical trials, 
low-dose calcium supplementation has been shown to 
reduce the risk of PE/E for pregnant women and preterm 
birth [14, 15, 22, 25, 26]. The World Health Organiza-
tion (WHO) currently recommends that 1.5–2.0 g of cal-
cium be taken daily during pregnancy for the prevention 
of PE/E, beginning at a gestational age of approximately 
20 weeks [27].
Screening and early identification of women at risk for 
PE/E may enable appropriate antenatal care (ANC), man-
agement, and treatment. Evidence from high resource 
settings on the cost-effectiveness of PE/E screening is 
favorable [28, 29]. Findings from 33 countries included 
in the Magnesium Sulphate for Prevention of Eclampsia 
(Magpie) Trial suggest that prophylactic treatment of 
PE/E with MgSO4 is cost-effective for severe cases and 
when magnesium sulfate is available at little to no cost 
[30]. Analysis of prophylaxis strategies in the United 
States determined that universal prophylaxis with MgSO4 
for all women with pre-eclampsia is cost-effective com-
pared with treating only those with severe disease [31]. 
Meta-analyses assessing the cost-effectiveness of test-
ing and treatment options for PE/E from the perspective 
of the United Kingdom’s National Health System sug-
gest that providing calcium to all women without initial 
screening for PE/E is the most effective “test/treatment” 
option [29, 32]. However, the existing literature fails to 
conclusively determine whether calcium supplemen-
tation interventions are cost-effective in low-income 
settings.
From May 2012 through August 2013, the Ministry 
of Health and Population (MOHP) in Nepal, with tech-
nical support from the USAID-funded Maternal and 
Child Health Integrated Program (MCHIP) and Jhpiego, 
implemented a pilot program testing the feasibility of 
providing calcium supplements to pregnant women to 
prevent PE/E. The objective of the overarching study 
was to evaluate this pilot program and generate evidence 
informing future decisions for scale up. The primary aim 
of this model-based sub-study is to determine the incre-
mental cost-effectiveness of calcium supplementation 
for PE/E prevention as compared to existing curative 
PE/E management in Nepal. Secondary objectives sought 
to explore the incremental cost effectiveness of three 
alternatives: (i) calcium supplementation in addition to 
MgSO4 (i.e. the existing standard of care), (ii) the existing 
standard of care, and (iii) no treatment for PE/E.
Ethical approval was obtained from Nepal Health 
Research Council and the Johns Hopkins University 




This pilot program was implemented in Dailekh District 
in the Mid-Western Region of Nepal based on the rec-
ommendations of a Technical Advisory Group formed to 
guide program implementation. Dailekh District, 650 km 
from Kathmandu, covers 1505 km2 with elevation ranges 
from 544 to 4168 m above sea level [33]. This mountain-
ous district was chosen because its terrain represents 
the most common type of district in Nepal while having 
a greater population. As a result, it may most accurately 
illustrate the challenges associated with implementa-
tion nationwide. Dailekh had an estimated population of 
264,616 in 2011, 51% of whom are women [33, 34].
The District Health Office provides preventive, cura-
tive, and promotional health services through 60 Health 
Facilities (HFs) [33]. Over 800 female community health 
volunteers (FCHVs) promote maternal and child health 
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services across the district, corresponding to 1 FCHV 
per 1000 population. Utilization rates for key reproduc-
tive, maternal, newborn and child health services exceed 
national level estimates for most critical indicators. Dur-
ing pregnancy, 29% of women report receiving no ANC 
services at all compared to a national rate of 15.2% [33, 
35]. Similar trends are reported for delivery careseek-
ing with 59% of women delivering with the assistance 
of a skilled birth attendant, compared to 36% of women 
nationally [33, 35].
Program
Project activities began in May 2012 and spanned 
through August 2013. Startup activities included the 
development of training manuals on calcium supplemen-
tation, behavior change communication (BCC) materi-
als, monitoring and evaluation tools, and initiation of 
training activities. Monitoring and evaluation tools were 
developed in line with the existing health management 
information system tools (i.e. calcium registers for ANC 
providers, calcium information added to existing FCHV 
registers, and reporting forms for village health workers 
and facility-level health providers). The supply of calcium 
supplements was purchased from Missionpharma India 
in 2012 and from Curex Pharmaceuticals Nepal in 2013.
To initiate district level activities, a half-day orienta-
tion was held for district level stakeholders. Four one-day 
training of district-level trainers with 95 attendees total 
followed. Sixty-one-day trainings at the health facil-
ity level trained all 268 ANC health workers in the dis-
trict, while another 60 one-day trainings trained all 810 
FCHVs. A full calcium supply and logistics support was 
provided to all health facilities. ANC health workers 
at government health facilities were trained to counsel 
pregnant women on the benefits of calcium supplemen-
tation during pregnancy and to distribute calcium during 
ANC visits. Health workers were also trained in the use 
of magnesium sulfate for treatment of severe PE/E and 
to perform PE/E screening using blood pressure meas-
urements and urine protein tests, conducted upon each 
ANC visit. Health facilities were provided with urine 
collection bottles and dipsticks to ensure the availabil-
ity of PE/E screening services for pregnant women dur-
ing ANC visits. FCHVs were trained to promote ANC 
attendance and compliance with the recommended cal-
cium regimen. Pregnant women attending an ANC visit 
were given a calcium supply for the remainder of their 
pregnancy. Women were typically provided with 300 cal-
cium tablets if enrolled at ≤5 months gestational age and 
100–200 tablets if enrolled at later gestational age. The 
recommended calcium intake was 1 g daily (2 tablets of 
500 mg each), beginning at 16 weeks gestational age until 
delivery.
Comparators
The national standard drug for treatment of severe 
PE/E in Nepal is MgSO4, administered by health facil-
ity providers following screening for PE/E [23]. Program 
activities sought to expand the existing standard of care 
to include the provision of calcium supplements (i.e. 
MgSO4  +  Calcium). In this analysis, we compare the 
costs and effects of the (i) MOHP calcium supplemen-
tation program in addition to the standard of care (i.e. 
MgSO4  +  Calcium) against two hypothetical arms, (ii) 
MgSO4 treatment alone (i.e. standard of care in Nepal) 
and (iii) no treatment.
Calculating costs
Economic costs, presented here in 2014 US dollars 
(USD), were assessed using a societal perspective, inclu-
sive of incremental costs to users and the government 
and/or health system. Program costs were obtained 
from financial records provided by implementing part-
ners (MCHIP and Jhpiego), and adjusted according to 
the 2014 consumer price indices and market exchange 
rates. An annualized factor comprised of a 3% discount 
rate and WHO-CHOICE life expectancy estimates 
were used to annualize capital costs [36]. Program costs 
included capital (equipment, supplies, initial trainings), 
and recurrent (supervision, personnel costs, calcium 
supplements and MgSO4 treatment, PE/E screening 
supplies, and IEC materials) costs required to start-up 
and support ongoing implementation [21]. While the 
pilot program experienced calcium supply costs from 
two sources as a result of supply shortage during imple-
mentation, modeled costs were calculated assuming no 
future shortfall in calcium supply. To estimate costs to 
users and incremental costs to health system, additional 
data were drawn from the literature and a survey imple-
mented by Jhpiego in three large government hospitals 
(Table  1). Based on survey findings, individual costs to 
hospitalize mothers, newborns, and PE/E cases were 
obtained, including costs of inpatient bed days, trans-
portation, hospital personnel, cesarean section proce-
dures, and other services.
Calculating effectiveness
Effects were calculated as disability-adjusted life years 
(DALYs) drawing from primary and secondary sources 
[37]. Estimates of the Years of Life Lost (YLLs) both to 
mothers and newborns were drawn from peer-reviewed 
literature, Nepal Demographic and Health Survey 2011, 
the Nepal Maternal Mortality and Morbidity Study 
2008/2009, and primary data collected by Jhpiego on the 
calcium supplementation program (Table  2). Resulting 
probabilities for maternal and newborn mortality were 
adjusted according to the treatment received via each 
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pathway through the model. Resulting effects were stand-
ardized to one million population.
The efficacy of MgSO4 treatment and cesarean section 
indicated as risk ratios were applied to outcomes accord-
ingly. Those with partial or low compliance with the 
full calcium regimen (300 tablets) were conservatively 
assumed to experience no effects of calcium supplemen-
tation in the prevention of PE/E. Because the relevant 
mortality risk data were unspecified, it was assumed that 
the probability of maternal and newborn death was simi-
lar for at-home and facility deliveries. The average age of 
a maternal death was 23.4 years based on the mean age of 
eclampsia patients in Nepal, and the life expectancy for 
females in Nepal was 69 years of age [38, 39]. Newborn 
YLLs were determined using the mean life expectancy 
of males and females in Nepal, which is 68 years of age 
[39]. To generate years lost to disability (YLDs), disabil-
ity weights for hypertensive disorders of pregnancy (0.00) 
[40] were used for mothers. The average age of onset 
used in the calculation of newborn YLDs was 0.0  years 
because mortality rates used in the model were associ-
ated with stillbirth.
Base case DALYs for mothers and newborns were dis-
counted at a rate of 3% without age weighting. Incremen-
tal DALYs averted through the calcium supplementation 
program were calculated separately for mothers and new-
borns using relevant parameters, and summed for each 
study arm to generate a summary estimate of DALYs for 
each arm.
Data analysis
TreeAge Pro ©2014 was used to generate a decision tree 
analytic model to conduct incremental cost-effectiveness 
analyses (Fig.  1). Analyses were built around the possi-
ble pathways of a pregnant woman and newborns with 
respect to PE/E. The tree was divided into three primary 
branches attributed to each arm of the study: (i) calcium 
supplementation in addition to MgSO4 (i.e. the existing 
standard of care), (ii) the existing standard of care, and 
(iii) no treatment for PE/E. For individuals enrolled to 
receive calcium supplementation in addition to MgSO4, 
additional branches were included for attending at least 
one ANC visit, coverage of calcium distribution (i.e. ges-
tational age at time of ANC visit), reported compliance 
with the full course of calcium, PE/E screening, onset of 
PE/E, hospitalization, MgSO4 treatment, cesarean sec-
tion, and final health status of mothers and newborns 
(i.e. healthy/recovery or death). For the comparator arms 
reflecting (ii) existing standard of care and (iii) no treat-
ment, similar sub-branches were used with the exception 
of those associated with calcium supplementation and 
MgSO4, as appropriate. The model represented a 1-year 
analytic time horizon consistent with the duration of the 
pilot program.
Comparisons of costs and effects for each study arm 
were used to generate incremental cost effectiveness 
ratios (ICERs). Variations in individual parameters were 
tested within this framework using one-way and multi-
way sensitivity analyses. The probabilities of compliance 
with the calcium regimen, risk ratio for the prevention 
of PE/E with calcium supplementation, and rates of 
screening, hospitalization, MgSO4 treatment, and cesar-
ean section were varied. The costs associated with cal-
cium supply, magnesium sulfate treatment, urine tests, 
and blood pressure testing were highlighted as costs of 
Table 1 Total costs and inputs in 2014 USD
Source: Jhpiego/MCHIP
Indicator Value Distribution 
for PSA
Total fixed program costs
 Start-up costs
  Capital $33,884.48 –
  Recurrent costs $10,919.61 –
  Total $44,804.09 –
 Implementation costs
  Recurrent costs $72,827.94 –
  Blood pressure instrument $24.25 –
  Total (not incl. variable costs, listed 
below)
$72,852.19 –
 Total program costs (per individual) $0.44
Variable costs per individual
 Urine test (sample bottle + dipstick) $0.07 Lognormal
 Calcium supply (per bottle, 100 
tablets)
$0.69 Lognormal
 MgSO4 treatment regimen $13.00 [21] Lognormal
 Mean daily bed fee for maternal 
hospitalization
$4.21 Lognormal
 Other maternal hospitalization costs $31.66 Lognormal
 Mean daily bed fee for newborn 
hospitalization
$8.25 Lognormal
 Other newborn hospitalization costs $21.11 Lognormal
Mean indirect costs per individual
 Daily wage in district $3.36 [42] Lognormal
 Round trip transportation for hospi-
talization
$29.67 [41] Lognormal
Mean duration of hospital stay
 Normal, healthy case
  Vaginal birth 1 day –
  Cesarean section 4.3 days –
  Live newborn 1 day –
 PE/E case
  Vaginal birth 6 days –
  Cesarean section 10 days –
  Live newborn 7 days –
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interest in these analyses as these were key commodi-
ties used in implementation of the program. These costs 
of interest as well as costs related to hospitalization were 
varied by 25% in sensitivity analyses with the exception of 
calcium supply, which had an upper bound of $1.42 USD 
per 100 tablets based on supplier prices (Table 1). Effects 
were varied from a base case of 3% discounting and no age 
weighting, to a high value under 3% discounting and age 
weighting and a low of 6% discounting and age weighting. 
A tornado diagram was generated to display variations in 
Table 2 Background epidemiological and program data
a Source: Jhpiego/MCHIP
b Discount rate 3% + no age weighting
c Discount rate 6% + age weighting
d Discount rate 3% + age weighting
Parameter Base case Low High Distribution for PSA
Maternal careseeking
 ANC, at least one visit 84.8% [35] 63.60% 100% Beta
 Facility deliveries in government sector 26.0% [35] 19.5% 32.5% Beta
Screening procedures
 Blood pressure 86.4% [35] 64.80% 100% Beta
 Urine sample 55.9% [35] 41.9% 69.9% Beta
 Blood sample 45.3% [35] 34.0% 56.63% Beta
Eclampsia epidemiology
 Incidence of eclampsia 4.30% [9] 3.23% 5.38% Beta
 Eclampsia as direct maternal cause of death 21.0% [10] 15.8% 26.3% Beta
 Mean age of eclampsia patients 23.4 [38] 17.7 [38] 29.2 [38] –
Treatment
 MgSO4 for PE/E management 68.9%a 51.7% 95.8% Beta
 Cesarean delivery 55.31% [46] 41.5% 69.1% Beta
Maternal risk ratios for PE/E
 Calcium supplementation 0.45 [15] 0.31 [15] 0.65 [15] Beta
 MgSO4, standard regimen 0.19 [19] 0.14 [19] 0.24 [19] Beta
 Cesarean delivery 0.55 [25] 0.41 [25] 0.69 [25] Beta
Still birth rates
 Vaginal birth 1.37%a 1.03% 1.71% Beta
 Cesarean delivery 0.43%a 0.32% 0.54% Beta
 Vaginal birth among PE/E cases 14.3%a 10.7% 17.9% Beta
 Cesarean delivery among PE/E cases 9.77%a 7.33% 12.2% Beta
Disability-adjusted life years (DALYs)
 DALYs averted per individual (maternal) 24.9b 15.6c 31.8d –
 DALYs averted per individual (newborn) 29.0b 16.4c 32.3d –
Pilot Program Data, Dailekh District, 2013
 Maternal careseeking
  ANC, at least one visit 94.6% 71.0% 100% Beta
 Calcium regimen compliance
  Full compliance 67.3% 50.5% 84.1% –
  Partial or low compliance 32.7% 24.5% 40.9% –
 Gestational age among women receiving calcium
  4–5 months (300 calcium tablets) 82.2% 61.7% 95% –
  6–7 months (200 calcium tablets) 13.8% 25.6% 2.5% –
  8–9 months (100 calcium tablets) 4.0% 12.8% 2.5% –
 Screening procedures
  Blood pressure 98% 73.5% 100% Beta
  Urine test 97% 72.8% 100% Beta
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Fig. 1 a Partial (two comparator arms shown) decision tree model of calcium supplementation program in Nepal. The segment in red is magnified.  
b Magnified inset: Decision tree model of calcium supplementation program for pregnant women in Nepal
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individual parameters in the univariate sensitivity analy-
sis. Probabilistic sensitivity analyses explored the effect of 
simultaneous variations in multiple parameters.
Thresholds for determining cost‑effectiveness
Overall findings on the cost per DALY averted for each 
option were evaluated according thresholds established 
in 2002 by the Commission on Macroeconomic and 
Health (CMH).1 Findings were additionally contextual-
ized against estimates of the cost per DALY averted for 
other low cost high priority interventions stipulated by 
Disease Control Priorities, 2nd ed. and other examples of 
calcium and MgSO4 programs published in the literature. 
Cost-effectiveness acceptability curves were generated to 
approximate the proportion of iterations that were cost-
effective for each study arm for willingness-to-pay 
(WTP) thresholds between $0 and $100 USD.
Results
Costs
Table  1 presents input parameters used to generate cost 
estimates. Start-up costs to provide calcium in addition 
to the existing standard of care were $44,804 and 1-year 
implementation costs were $72,852; these values corre-
spond to a program cost per person per year of $0.44. Costs 
to users, which included transportation and daily wages 
lost, were $29.67 [41] and $3.36 [42], respectively. Variable 
costs for patient care included screening ($0.07), calcium 
supply ($0.69 per 100 tablets), the total cost of medicines 
and procedures associated with MgSO4 treatment ($13.00) 
[21], and daily bed fees for mothers ($4.21) and newborns 
($8.25). Table 3 outlines the total costs associated with each 
condition considered in the model. Total inpatient costs to 
the health system were calculated according to the mean 
duration of hospital stay by health condition. The average 
duration of hospital stay for PE/E cases was estimated to 
be six days, and for those undergoing cesarean section, ten 
days. Newborns delivered by PE/E mothers remained hos-
pitalized for an average of 7 days.
Effects
All pregnant women attending at least one ANC visit 
were provided with a calcium supply corresponding 
to gestational age. ANC users at 4 or 5 months of preg-
nancy (82.2%) received 300 tablets, at 6 or 7  months 
(13.8%) received 200 tablets, and at 8 or 9 months (4.0%) 
1 The CMH stipulated that an intervention is highly cost effective (HCE) 
if it has a cost per DALY averted which is lower than the Gross Domestic 
Product (GDP) per capita. Interventions with a cost per DALY averted of 
less than 3 times the GDP per capita are deemed cost effective, while those 
with a DALY averted which is 3 times that of the GDP are considered cost 
ineffective. Considering costs according to these standardized thresholds 
will help to facilitate the interpretation of findings by decision-makers.
received 100 tablets (Table  2). Of those women receiv-
ing calcium supplements, 67.3% reported adherence 
to the full course. The remaining 32.7% reported either 
completing a partial course or low compliance with the 
calcium regimen. Among women in the pilot program, 
the added probability of getting screened for PE/E risk 
through blood pressure measurement or urine testing 
was high (99.94%). The average risk ratio of PE/E with 
calcium supplementation during pregnancy is 0.45 (95% 
CI: 0.31, 0.65) [15]. This efficacy was applied in the model 
only for those women receiving and compliant with the 
full course (300 tablets) of calcium supplementation.
The proportion of births delivered in government facil-
ities nationally (26%) was used as a proxy measure for 
the rate of hospitalization in Nepal since these data were 
not readily available, either nationally or from program 
data [35]. Among surveyed government hospitals, 68.9% 
of women received m MgSO4 treatment for severe PE/E 
management. This value was used to indicate the propor-
tion of women receiving MgSO4 sulfate treatment. The 
efficacy of MgSO4 in the treatment of PE/E used in the 
analysis was a risk ratio of 0.19 [19]. The probability of 
a cesarean section for inpatients of government hospi-
tals was determined by the rate of cesarean sections as a 
mode of delivery (55.3%) and their availability in govern-
ment hospitals (71%) [10, 19]. The mortality rate used for 
pregnant women in the model was specific to eclampsia 
as a direct cause of maternal death (21%) [10]. Table  3 
indicates the total effects associated with each condition 
considered in the model.
Incremental cost‑effectiveness
Table 4 presents incremental cost-effectiveness ratios for 
MgSO4 vs. no treatment; MgSO4 + calcium vs. no treat-
ment; and MgSO4 + calcium vs. MgSO4. Figure 2 depicts 
the cost-effectiveness plane showing mean estimates for 
10,000 iterations of total costs and effects, while Fig.  3 
present incremental cost-effectiveness scatter plots for 
each alternative considered. MgSO4 vs. no treatment 
was associated with a cost per DALY averted of $3.40 
($2.60–4.00) USD. MgSO4  +  calcium vs. no treatment 
corresponded to a cost per DALY averted of $17.50 
($17.14–19.69) USD. When compared to the existing 
standard of care, the calcium program yields a cost per 
DALY averted of $25.33 ($25.22–29.50) USD.
Table 3 Summary of total costs and effects by comparator
Condition Total costs Total effects
No treatment $26.82 52.58
MgSO4 $26.98 52.68
MgSO4 + calcium $29.29 52.71
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One-way sensitivity analyses revealed that incremental 
cost-effectiveness ratios were driven by four key param-
eters: (1) hospitalization for facility delivery, (2) cost of 
hospitalization, (3) cost of cesarean section, and (4) the 
probability of developing PE/E (Fig. 4). Probabilistic sen-
sitivity analyses simulated the effect of simultaneous vari-
ations in multiple iterations (10,000). Findings suggest 
that the addition of calcium to the existing standard of 
care (MgSO4) is favored above a WTP threshold of ~$30 
USD and has an 84% probability of being cost-effective 
above $40 USD (Fig.  5). When compared against a sce-
nario of no treatment, MgSO4 + calcium is the preferred 
strategy for WTP thresholds of $25 or more. When 
considered independently of calcium supplementation, 
MgSO4 vs. no treatment is 100% cost-effective above 
WTP thresholds of $10 USD.
Discussion
Study findings suggest that MgSO4 treatment of PE/E in 
Nepal is cost-effective when compared to no treatment 
at all. The addition of calcium supplementation increases 
costs and corresponds to a minor increase in effective-
ness when compared against a scenario of no PE/E man-
agement. Despite the low incremental cost-effectiveness 
ratios across comparisons, findings suggest that for 
individuals only willing to pay $10 USD or less, MgSO4 is 
the preferred strategy for preventing PE/E. However, for 
individuals willing to pay more than $35 USD, calcium in 
addition to MgSO4 offers the best value for money.
When compared against alternative resource uses, 
MgSO4 + calcium and MgSO4 compare favorably against 
alternative low-cost high-priority interventions rec-
ommended for adoption in South Asia (Table  5). These 
interventions include increased primary care coverage, 
improved quality of comprehensive emergency obstet-
ric care, improved overall quality and coverage of care, 
and neonatal packages targeted to families, communi-
ties, and clinics (Table 5). Beyond comparison with other 
health interventions, we compared study findings with 
those observed in other economic evaluations of PE/E 
treatment and prevention programs. In the Magpie Trial 
determined the incremental cost-effectiveness of prophy-
lactic MgSO4 for 9996 women with pre-eclampsia from 
33 countries; the incremental cost of preventing one case 
of eclampsia was $456 in low GNI countries and reserv-
ing MgSO4 prophylaxis for only severe cases of PE/E 
reduced this estimate to $263 [30]. Overall, the findings 
of this study fall well beneath the cost per DALY averted 
estimates observed in Magpie. However, limitations in 
available data, including those surrounding maternal and 
Fig. 2 Cost-effectiveness plane showing mean estimates for 10,000 iterations of total costs and effects
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Fig. 3 Incremental cost-effectiveness scatter plot for comparison of three alternatives. Gray line indicates 95% confidence interval. a (i) calcium 
program vs. (ii) standard of care; b (i) calcium program vs. (iii) no treatment; c (ii) standard of care vs. (iii) no treatment
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newborn health effects, may contribute to the disparities 
observed.
Beyond efforts to contextualize study findings with 
alternative programs and resource uses, we consid-
ered findings against the gross domestic product (GDP) 
of Nepal of $697 per capita in 2014 [44]—the thresh-
old value for cost-effectiveness established by WHO 
CHOosing Interventions that are Cost Effective (WHO-
CHOICE) and CMH [45]. The model demonstrates that 
calcium supplementation in addition to MgSO4 becomes 
more cost-effective with increased rates of PE/E. This 
suggests that the intervention would offer the greatest 
value for money in districts with higher incidence rates of 
the disease. If calcium supplementation is to be nation-
ally adopted, targeting prevention efforts where inci-
dence of PE/E is particularly high is recommended.
In 2005, the Government of Nepal established the 
Aama program, or Safe Delivery Incentive Program 
(SDIP), a demand-side financing scheme providing 
incentives to women to deliver in health facilities in 
order to improve mothers’ health outcomes and that of 
their child. In January 2009, user fees were removed for 
all types of delivery in government health facilities as well 
as selected accredited private hospitals. Under the Aama 
program, cash payments in the amount of NPR 500–1500 
($5.28–15.83 USD) depending on district terrain are 
made to women to pay for transportation to facilities for 
delivery [43]. The Aama program also provides incentives 
to the health facility for deliveries; participating health 
facilities are reimbursed NPR 1000–1500 ($10.55–15.83 
USD) for normal deliveries, NPR 3000 ($31.66 USD) for 
complicated deliveries, and NPR 7000 ($73.87) for cesar-
ean deliveries [43]. However, our model estimates these 
costs based on surveys conducted at three government 
hospitals. Survey findings indicated higher mean costs 
associated with transportation and hospitalization by 
type of delivery, thereby providing more conservative 
estimates of anticipated costs incurred by users and the 
health system.
The majority of cost-effectiveness drivers are associ-
ated with processes tied to hospitalization. Increases in 
the rates of hospitalization for facility delivery generally 
resulted in increased costs per DALY averted, suggesting 
that costs bring about greater impact on cost-effective-
ness ratios than the health effects brought about by this 
intervention. Effectiveness data specific to the nuances 
of compliance to the calcium regimen and for women of 
different levels of risk of onset would provide better evi-
dence in this regard.
Hospitalization for facility delivery is directly linked 
with the probability of receiving MgSO4 treatment and/
or undergoing a cesarean section for PE/E. The cost of 
hospitalization and the additional cost of cesarean sec-
tion procedures constituted the highest cost values incor-
porated into the model. As a significant proportion of 
overall costs, it corresponds that these cost factors have 
a greater impact on incremental cost-effectiveness ratios 
when varied. Still, with improved utilization of facilities 
for delivery, it may be possible to decrease the costs of 
hospitalization and cesarean section procedures and gen-
erate overall better health outcomes with PE/E hospitali-
zation and treatment.
Fig. 4 Tornado diagram (net benefits) illustrating the key drivers of cost-effectiveness. The base ICER is set at $26.84 per DALY averted in the dia-
gram. Varying rate of facility delivery resulted in the greatest change in ICER, while varying hospitalization costs for PE/E cases resulted in the least 
change
Page 12 of 15Feldhaus et al. Cost Eff Resour Alloc  (2016) 14:13 
Page 13 of 15Feldhaus et al. Cost Eff Resour Alloc  (2016) 14:13 
Increased use of calcium supplementation for the pre-
vention of hypertensive disorders of pregnancy in the 
South Asia region may also result in reductions in the 
cost of calcium supply, further improving cost-effec-
tiveness. A critical factor in determining whether or not 
mothers receive calcium supplementation and/or early 
treatment is ANC utilization. The Government of Nepal 
introduced the 4ANC incentive program in July 2009, 
providing cash payments to women NPR 400 upon fol-
lowing the ANC protocol of four ANC visits at specific 
gestation times, institutional delivery, and a postnatal 
visit [43]. Further increasing ANC and early ANC may 
serve to further increase use of and adherence to cal-
cium. The combination of these efforts for the prevention 
of PE/E may culminate into a synergistic effect for opti-
mal cost-effectiveness for Nepal and similar settings.
Limitations
This analysis was carried out retrospectively as part of the 
evaluation of a small-scale pilot program in the Dailekh 
District of Nepal. In the absence of a comparison area, 
the program is compared against hypothetical compara-
tors of no calcium distribution to women during ANC. 
As extended observation of person-time spent adminis-
tering calcium supplementation and counseling was not 
conducted as part of this pilot program evaluation, the 
time of health care providers to administer and counsel 
patients has not been included in this analysis. In the 
model, utilization of MgSO4 and cesarean delivery as a 
treatment for PE/E and their respective effects remained 
the same across arms regardless of case severity. Sever-
ity can also have considerable implications for morbid-
ity and mortality that affect results. Differences in PE/E 
Table 5 Cost per DALY averted associated with low-cost high-priority interventions recommended for South Asia
The italicized text denotes the study program in Nepal and aims to contextualize our findings against those of alternative resource uses recommended by the Disease 
Control Priorities (2nd ed)
Low‑cost high‑priority interventions recommended for South Asia Mean cost per DALY averted (USD)
Childhood immunization $8.00 [47]
 Additional coverage of traditional Expanded Program on Immunization
Full course calcium supplementation (82.2%) with 67.3% compliance in addition to MgSO4 (68.9%) in Nepal $25.33
HIV/AIDS $9–126 [47]
 Voluntary counseling and testing
 Peer-based programs targeting at-risk groups
 School-based interventions that disseminate information to students
 Prevention of mother-to-child-transmission with antiretroviral therapy
Surgical services and emergency care $6–212 [47]
 Surgical ward in a district hospital
 Staffed community ambulance
 Training of lay first responders and volunteer paramedics
Tuberculosis $8–263 [47]
 Childhood vaccination against endemic TB
 Directly observed short-course chemotherapy
 Isoniazid treatment of epidemic TB
 Management of drug resistance
Using MgSO4 prophylaxis for only severe cases of pre-eclampsia in low GNI countries $263.00 [30]
Maternal and neonatal care $127–394 [47]
 Increased primary care coverage
 Improved quality of comprehensive emergency obstetric care
 Improved overall quality and coverage of care
 Neonatal packages targeted to families, communities, and clinics
Incremental cost of preventing one case of eclampsia using MgSO4 in low GNI countries $456.00 [30]
(See figure on previous page.) 
Fig. 5 Cost-effectiveness acceptability curves for three alternatives. a Calcium program (blue) vs. standard of care (red); b Calcium program (blue) vs. 
no treatment (red); c Standard of care (blue) vs. no treatment (red). The curves represent the percentage of iterations that were cost-effective (y-axis) 
for varying willingness-to-pay thresholds in 2014 US$ up to a ceiling $100. Findings suggest that the addition of calcium to the existing standard 
of care (MGSO4) is favored above a WTP threshold of ~$30 USD. When compared against a scenario of no treatment (B), MgSO4 + calcium is the 
preferred strategy for WTP thresholds of $25 or more. When considered independently of calcium supplementation, MGSO4 vs. no treatment is 
considered good value for money above WTP thresholds of $10 USD
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management according to case severity were not mod-
eled because limited data exists describing differentiated 
effects for mothers and newborns based on PE/E severity.
We note that women attending at least one ANC visit 
may have a greater rate of hospitalization for various rea-
sons. It is also possible that there is a greater hospitaliza-
tion rate and treatment measures provided for mothers 
experiencing more severe PE/E. These nuances are not 
captured in the model due to lack of differentiated data. 
Beyond these parameters, the model relies upon second-
ary data to address gaps in primary data on mortality and 
many of the provider and users’ cost categories. Primary 
data on reported compliance with calcium regimens pro-
vided were drawn from household survey data provided 
by the program and may be vulnerable to recall bias.
Conclusions
Calcium supplementation for pregnant mothers provided 
with appropriate MgSO4 treatment holds promise for the 
cost-effective reduction of maternal and neonatal mor-
bidity and mortality associated with PE/E. As modeled 
by the MOHP calcium supplementation pilot program 
in Nepal, such calcium interventions may be similarly 
cost-effective in other low-income settings. Additional 
research is recommended to further explore the impli-
cations of calcium on newborn outcomes and delivery 
at scale. Future research is needed to understand factors 
that may improve early initiation of ANC and increase 
rates of facility delivery. Efforts to deliver calcium at scale 
offer the potential to yield even greater cost-effectiveness 
given the high utilization of ANC—the delivery point of 
calcium supplementation.
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